Business Of Biotech
The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.
Episodes
258 episodes
The Discovery Of Microbes And Implications For Public Health Today, With Science Writer Thomas Levenson
On this week's episode, Thomas Levenson, MIT professor and author of So Very Small: How Humans Discovered The Microcosmos, Defeated Germs — And May Still Lose The War Against Infectious Disease talks about what...
•
Episode 257
•
1:06:27
Psychedelics For Mental Health Disorders With atai's Srinivas Rao, M.D., Ph.D.
On this week's episode, Dr. Srinivas Rao, co-founder and CEO at atai Life Sciences, explains how his engineering background led him to the development of psychedelic compounds for treating depression, anxiety, and other mental health disorders....
•
Episode 256
•
55:50
Biotech Angel Investing With Yaniv Sneor
On this week's episode, Yaniv Sneor, founder of the Mid Atlantic Bio Angels and CEO at Native State Therapeutics, explains how life science angel investors evaluate biotech startups, and offers tips for young drug developers in search of fundin...
•
Episode 255
•
56:27
Leading A tRNA Startup With Alltrna's Michelle Werner
On this week's episode, Michelle Werner, CEO at Alltrna, talks transfer RNA (tRNA) therapy with host Ben Comer and guest co-host Anna Rose Welch, editorial and community director at Advancing RNA. Wer...
•
Episode 254
•
59:23
Executing A Product Pivot With Vir Bio's Mark Eisner, MD
On this week's episode of the Business of Biotech, Dr. Mark Eisner, EVP and Chief Medical Officer at Vir Bio, talks about the company's post-COVID pivot into infectious diseases (Hepatitis Delta and Hepatitis B) and oncology (solid tumors), how...
•
Episode 253
•
39:45
Commercializing RNAi Therapies With Alnylam's Tolga Tanguler
On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, the company's use of value-based contracts, a...
•
Episode 252
•
55:54
Big Pharma Insights For Building Biotech Startups With Uniquity Bio's Brian Lortie
On today's episode I'm speaking with Brian Lortie, President and CEO of Uniquity Bio, about his "no jerk" policy and how his experience building teams at GSK, Endo Pharmaceuticals, and Onspira Therapeutics informs his leadership at Uniquity, a ...
•
Episode 251
•
55:45
The Implications Of China's Growing Biotech Industry With Allan Shaw
Business of Biotech MVP Allan Shaw is back to talk about the rise of China's biotech sector, and its evolution from fast follower to global innovation powerhouse. Increased deal activity with Chinese biopharmaceutical companies is injecting new...
•
Episode 250
•
46:08
How To Be A CFO With Insmed's Sara Bonstein
On today's episode we're speaking with Sara Bonstein, Chief Financial Officer at Insmed, about what it takes to be a successful CFO. Sara provides useful insights on how to lead teams, especially when those teams have deeper subject matter expe...
•
Episode 249
•
44:20
Deal And Investment Trends With Investment Banker David Sans
Today we're talking life sciences investment trends and risks with David Sans, an investment banker with an academic background in chemical engineering and molecular modeling, and a professional background that began in Big Pharma and shifted t...
•
Episode 248
•
46:43
Business of Biotech 2.0 with Ben Comer
After nearly five years as host of the Business of Biotech podcast, Matt Pillar is handing the mic over to the voice of the Business of Biotech 2.0, veteran life sciences journalist Ben Comer. On this epsiode, Ben shares his nearly 20-year jour...
•
34:44
BoB@JPM: Nima Farzan, Latigo Biotherapeutics
In this final installment of our episodes recorded and filmed on-site at the JP Morgan Healthcare Conference, Nima Farzan, CEO of Latigo Biotherapeutics, shares his company's mission to change the pain management paradigm by way of novel, non-o...
•
Episode 246
•
43:32
BoB@JPM: Kasper Roet, Ph.D., QurAlis
Dr. Kasper Roet's hands-on work at the Dutch Brain Bank informed his leadership at the biotech QurAlis, where three clinical programs targeting specific genetic mechanisms in ALS are now underway. On this episode of the Business of Biotec...
•
Episode 245
•
43:46
BoB@JPM: Rick Modi, Affinia Therapeutics
The latest in our series of Business of Biotech podcasts recorded in-person at JPM in San Francisco features an inspiring conversation with Affinia Therapeutics CEO Rick Modi. Modi shares on how his upbringing in Kenya shaped his adversity-embr...
•
Episode 244
•
52:20
BoB@JPM: Owen Hughes & Brad Sitko, XOMA Royalty
On this episode of the Business of Biotech, recorded on-site at the 2025 JP Morgan Healthcare Conference, we explore a new approach to biotech financing with XOMA Royalty's Owen Hughes and Brad Sitko. The CEO and CIO, respectively, share an inn...
•
Episode 243
•
56:27
BoB@JPM: Tom Chalberg, Ph.D., Genascence
Recorded in-person at the JP Morgan Healthcare Conference in San Franscisco, this episode finds Matt Pillar and Ben Comer exploring the evolution of gene therapy with Dr. Tom Chalberg, Founder, Chairman, & CEO at Genascence. We discuss ATMP...
•
48:00
BoB@JPM: Ran Zheng, Landmark Bio
Ran Zhang was hire number one at Landmark Bio back in 2021. Today, she's CEO of the 70+ employee cell and gene therapy manufacturer. We caught up with her and Life Science Leader chief editor Ben Comer at the JP Morgan Healthcare Conference in ...
•
Episode 241
•
37:00
BoB@JPM: Peter Anastasiou, Capsida Biotherapeutics
From the JP Morgan Healthcare Conference in San Francisco, Peter Anastasiou, CEO of Capsida Biotherapeutics, discusses his journey from big pharma to biotech and the challenges he's faces on the leading edge of first-gneration gene therapies. A...
•
Episode 240
•
45:07
BoB@JPM: Stefan Scherer, M.D., Ph.D., 3T Bioscience
From the JP Morgan Healthcare Conference in San Francisco, Dr. Stefan Scherer shares insight from 3T Bioscience's transition from clinical medicine to drug development, and his experiences in biotech leadership along the way. Dr. Scherer discus...
•
Episode 239
•
43:00
The Business Of CNS with Acumen's Jim Doherty, Ph.D.
Life Science Leader's Ben Comer and Acumen Pharmaceuticals' Dr. Jim Doherty join the Business of Biotech to discuss Dr. Doherty's lifelong, singular focus on researching therapeis for CNS diseases. We cover the historical challenges associated ...
•
Episode 238
•
47:51
High-Throughput Discovery With Bioptic's Andrey Dobry
Andrey Doronichev, known to many simply as Dobry, is perhaps best known for taking YouTube mobile. You heard that right. If it weren't for him and the teams he led, YouTube might still be a desktop experience. He went on to lead product strateg...
•
Episode 237
•
1:13:36
RNA Sandbox with Johns Hopkins RNA Innovation Center's Jeff Coller, Ph.D. and Michelle Kim, Ph.D.
In close partnership woth Johns Hopkins and TriLink BioTechnologies, Jeff Coller, Ph.D. and Michelle Kim, Ph.D. have built a sandbox for RNA developers and aspirational RNA business builders to play in. On this week's episode of the Business of...
•
Episode 236
•
1:06:32
Biotech Story Time With Tal Zaks, M.D. (Part 2, Tall Tales with Tal)
Dr. Tal Zaks is back, along with Advancing RNA's Anna Rose Welch, for part 2 of "Story Time With Tal." On this week's episode, we turn from his time navigating medical affairs as CMO at Moderna during the COVID 19 pandemic to learn about his la...
•
Episode 235
•
54:04
Risk Mitigation With Meira GTx's Zandy Forbes, Ph.D.
Zandy Forbes, Ph.D. learned about business risk mitigation in the riskiest of business environments. She was a public markets healthcare investor on Wall Street for well more than a decade. Her hedge fund experience followed the Human Frontiers...
•
1:02:34
Biotech Story Time With Tal Zaks, M.D. (Part 1)
Tal Zaks, M.D. was Chief Medical Officer at Moderna before, during, and immediately following the company's headline role during the COVID pandemic. If that doesn't pique your interest about the stories he can tell, this episode of the Business...
•
Episode 233
•
55:25